Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb

Launched by RENJI HOSPITAL · Mar 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat a condition called deep vein thrombosis (DVT), which occurs when a blood clot forms in the deep veins of the leg. The researchers are exploring a method called rheolytic thrombectomy, which aims to improve how effectively blood clots are removed from the veins. The goal is to achieve better results than current treatments and reduce the chances of long-term complications, such as post-thrombotic syndrome, which can cause pain and swelling in the affected leg.

To participate in the trial, individuals must be between 18 and 80 years old and have experienced symptoms of acute DVT within the past 14 days. They should have clots involving specific veins in the leg. However, certain people may not be eligible, such as those with a history of DVT in the same leg, severe kidney issues, or allergies to specific blood-thinning medications. Participants will be required to provide informed consent, meaning they understand the trial and agree to take part. Throughout the study, participants can expect close monitoring and care as they undergo this innovative treatment approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18-80 years old;
• • Acute DVT with clinical symptoms occurred less than 14 days since the onset of disease;
• • DVT with thrombosis involving the iliac vein, common femoral vein, distal popliteal vein, and/or calf vein;
• • Informed consent signed by patients.
• Exclusion Criteria:
• • Patients with the previous history of the same side of lower-limb DVT;
• • Patients with plasma Creatinine level greater than 180umol/L;
• • Patients who are contraindicated to thrombolysis;
• • Patients with inferior vena cava thrombosis;
• • Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent;
• • Patients who have participated in a clinical trial in the past three months;
• • Women during pregnancy and lactation
• • Patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\<2 years);
• • Patients with autoimmune thrombopathy or thrombocytopenia (platelets \< 80·10⁹/L);
• • Patients who are unable or unwilling to participate in the study.